Document ExjXBLmq2XnDkVRVXBpXYYnpn

NS AR22 -- 156 30 = E. I. bu Pon a bea Nemour&s Company PankeRPs.uOU.RGB.oxW.12V1a7.) 2si0t FouvMER PROGUCTS CEARTMENT ` p7e4r,mitRegpiroongra[m1s1 Monitoring Unit, ENT P6hthilaadnedlpWhailan,utPeSntnrseyeltvsania 19106 CW..VRao.nalDdiv.Saondfy,WatSeurperRveissoourrces P3a2r1kerEsnbeurrsgo,n WAYvenu2e6101 dune 9, 198) RETURCNERTRIEFCIEEIDPTMARIELQUE-STED DW.aviVda. W.DivRiosbiionnsono,f CWhaiteefr Resources 1C2h0a1rleGsrzeoenn,briWeVr S25t3r1e1et : Dear Sir: fron our Tshuipsplileertteorf itshetosurifnafcotrnantyouammofonituomxicpietryfluionrfooorcmtaatnioosntew,e ahlasvoe krneocweniveads FcCo-n1c8e3n,tratwihoinch ofisabopurtese0n.t1 mign/L.our Thoeutf3allCom0p0a5ny (phaesrmiatdvi(sWeVdOGOus127t5h)at intnisa mtautbeersiatlo hfeesmalbeeenratfsounidn teo pcraeulsiemidneafreyctlsaboinrattohrey uenxbpoerrnimwehnetn. FC-143 in the manufacture of fluoropolymer resins. feOdu byontstoumsaecsh the 3M exMpuecrhimemnotr.e teAsstipnagrtmuosft tbhee coonngdouicntgedprtoogrdaemtetromidneetertmheinesigthneifiscaafnectey ooff oduertaimlaetderieaxlpse,ribmoetnhts.Du PHoonwte'vserH,askweellhaLvaebotraakteonrythaend pr3eMcaaurteionnowofplarnenaisnsgigmnoinrge fFelmuaolreopopleyrmseornnerlesionfs acrheilmdabneuafraicntgurceadpaobrilFiCt-y183to1sarheaansdleodu.tside those in which preliminarAty atnhiimsal tiemxep,eriwmeentd.o noFtC-1k4n3owhasthebeesnigniinfiucsaencef,or idfecaandye,s woifthotuhte apparent adverse affects in humans. If you need additional information, please let me know. A1c3k0:6h8ew 2 A.C st7 on EWnavsihrionngmteonntaWlorkCsontrol Consultant : There's 3 wend of things we're15doing something aces Attachmen3t